• Explore /
  • Poster
  • / PIONEER: A multicenter, open-label, randomized phase II trial of second-line apatinib plus chemotherapy versus chemotherapy alone in gastric and gastroesophageal junction adenocarcinoma (GA/GEA) refractory to or intolerant of prior anti-PD-1 therapy.

PIONEER: A multicenter, open-label, randomized phase II trial of second-line apatinib plus chemotherapy versus chemotherapy alone in gastric and gastroesophageal junction adenocarcinoma (GA/GEA) refractory to or intolerant of prior anti-PD-1 therapy.

Abstract Poster

Authors

null

Dandan Yu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Dandan Yu , Hongli Liu , Jianli Hu , Hong Ma , Jun Xue , Junli Liu , Jing Wang , Zhenyu Lin , Min Jin , Shengli Yang , Lei Zhao , Tao Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05029453

DOI

10.1200/JCO.2022.40.4_suppl.TPS361

Abstract #

TPS361

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Yuanyuan Zhao

First Author: Feng Wang

First Author: Johanna C. Bendell

First Author: Wensi Zhao